Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for the inspection carried out at New Injectable Facility (F-3) at Karakhadi, Gujarat during the period from January 28, 2021 to February 06, 2021, indicating that the USFDA finds company’s responses to their observations to be adequate. USFDA has also indicated that compliance verification would be performed during re-inspection of the said Facility in the next review cycle.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
